Form 4: Verrica Director Manning Invests $17.5M in Stock & Warrants

Verrica Pharmaceuticals Director and 10% owner Paul B. Manning acquired over $17.5 million in common stock and Series C warrants.

Summary

• Paul B. Manning, a Director and 10% owner of Verrica Pharmaceuticals Inc. (VRCA), made significant purchases of the company's securities on November 25, 2025.
• Manning acquired 1,375,380 shares of common stock directly (jointly with his spouse) and 2,750,762 shares indirectly (via BKB Growth Investments, LLC).
• These common stock acquisitions were part of investment units purchased at $4.2425 per unit, totaling approximately $17,508,000.10.
• Each investment unit also included a Series C warrant for one-fourth of a share of common stock, leading to the acquisition of 343,845 direct and 687,690 indirect Series C warrants.
• The Series C warrants are immediately exercisable at a price of $6.315 per share and expire on November 25, 2030.
• The reported numbers reflect adjustments made due to a 1-for-10 reverse stock split effected by the Issuer on July 24, 2025.
• Manning's beneficial ownership following these transactions includes 3,958,189 direct common shares, 3,348,372 indirect common shares via BKB Growth Investments, LLC, and additional indirect holdings through various trusts and PBM Capital Investments, LLC.

Sentiment

Score: 8

Explanation: The significant insider purchase by a director and 10% owner, totaling over $17.5 million, indicates strong confidence in the company's future prospects. While a reverse stock split occurred, the current action is a strong positive signal from an informed insider.

Positives

• Significant insider buying by a Director and 10% owner, Paul B. Manning, indicates strong confidence in the company's future prospects.
• The substantial investment of over $17.5 million demonstrates a long-term commitment from a key stakeholder.
• Acquisition of both common stock and warrants suggests a belief in potential future stock price appreciation.

Risks

• The Series C Warrants have an exercise price of $6.315, which is higher than the $4.2425 purchase price of the investment units, implying the stock needs to appreciate significantly for the warrants to be in-the-money.
• A 1-for-10 reverse stock split was effected on July 24, 2025, which can sometimes be a sign of a company struggling to maintain a certain stock price level or meet exchange listing requirements.
• Beneficial ownership limits for warrant exercise (49.99%) could restrict full exercise if the reporting person's ownership approaches this threshold.

Future Outlook

The acquisition of Series C Warrants with an expiration date of November 25, 2030, suggests a long-term positive outlook on Verrica Pharmaceuticals' stock performance, anticipating appreciation above the $6.315 exercise price.

Management Comments

• The shares are held by Mr. Manning jointly with his spouse.
• The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
• The Reporting Person disclaims beneficial ownership of these securities [held in trusts for immediate family members], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• The Reporting Person is the trustee of The Paul B. Manning Revocable Trust and has sole voting and investment power with respect to the shares held by the Trust.
• The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.
• The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

Industry Context

This insider purchase by a significant shareholder and director in a pharmaceutical company suggests confidence in the company's pipeline, market position, or future regulatory approvals, potentially signaling a belief that the company is undervalued or poised for growth within the competitive pharmaceutical sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The significant insider purchase could be viewed positively, signaling management confidence and potentially attracting other investors.

Next Steps

• Monitoring future Form 4 filings for additional insider activity.
• Observing Verrica Pharmaceuticals Inc.'s stock performance relative to the warrant exercise price of $6.315.
• Analyzing the company's operational and financial reports for developments that might justify the insider's confidence.

Key Dates

Recommendation

The substantial insider purchase by Paul B. Manning, a Director and 10% owner, signals strong confidence in Verrica Pharmaceuticals' long-term prospects. This level of investment, totaling over $17.5 million, is a positive indicator. However, the recent 1-for-10 reverse stock split, while adjusted for in the reported numbers, often suggests past challenges. The Series C Warrants' exercise price of $6.315 is also above the $4.2425 unit purchase price, meaning the stock needs to appreciate significantly for the warrants to be profitable. Given these factors, a 'hold' recommendation is prudent, acknowledging the insider's conviction while awaiting further operational or financial catalysts to justify a stronger 'buy' position.

Keywords

Verrica Pharmaceuticals, VRCA, Insider Buying, Form 4, Paul B. Manning, Stock Purchase, Warrants, Beneficial Ownership, Reverse Stock Split, Director, 10% Owner, Pharmaceuticals